[Asia Economy Reporter Hyunseok Yoo] HLB Life Science has introduced an anticancer candidate substance with a mechanism that induces cancer cell death by inhibiting the cell cycle.
On the 18th, HLB Life Science announced that it has acquired all rights, including patents, for anticancer candidate substances developed as treatments for various solid cancers such as lung cancer, breast cancer, colon cancer, and pancreatic cancer, from the domestic bio company LSK NRDO.
The newly introduced anticancer substance has a mechanism that regulates signals involved in the cell cycle to inhibit the proliferation of cancer cells. This mechanism has recently attracted significant attention from anticancer drug developers.
The cell cycle refers to the life cycle of a cell from the parent cell dividing into two daughter cells and passing on genetic material. Cells typically repeat a four-stage cycle (G1 phase → S phase → G2 phase → M phase) during cell division.
The new substance introduced by HLB Life Science inhibits cell division by interfering with the progression from the G2 phase to the M phase of the cell division cycle, thereby suppressing cancer cell growth and inducing cell death.
Han Yonghae, CEO of HLB Life Science, said, “The anticancer drug group secured through this contract consists of new mechanism anticancer drugs that are distinct from existing treatments. HLB Life Science now owns patent rights in major countries including Korea, the United States, Europe, Japan, and China, covering patents, development, production, sales, and all rights related to future technology transfers for these substances. We plan to focus intensively on preclinical research and development to rapidly advance to the clinical stage as potent solid cancer treatments.”
HLB Life Science owns domestic rights and some rights in Europe and Japan for the small molecule anticancer drug substance rivoceranib, which inhibits angiogenesis (VEGFR-2 inhibition), and is conducting clinical trials for various indications including stomach cancer, liver cancer, rectal cancer, salivary gland cancer, and tumors in companion animals. Additionally, it has secured Korean rights for pyrotinib, targeting EGFR, HER2, and HER4, and is conducting clinical trials as a treatment for breast cancer and lung cancer.
Recently, HLB Life Science established a new drug research institute to strengthen its new drug research and development capabilities and is actively promoting open innovation with domestic and international companies and research institutions, focusing on expanding its pipeline.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
